Aficamten, a cardiac myosin inhibitor, has shown promising results in clinical trials for the treatment of obstructive hypertrophic cardiomyopathy (oHCM). The Phase 3 SEQUOIA-HCM trial demonstrated ...
Results that may be inaccessible to you are currently showing.